Therapeutic Potential of Salicylamide Derivatives for Combating Viral Infections

Overview

Journal Med Res Rev

Publisher Wiley

Specialties General Medicine
Pharmacology

Date 2023 Mar 11

PMID 36905090

Authors

Jimin Xu

Yu Xue

Andrew A Bolinger

Jun Li

Mingxiang Zhou

Haiying Chen

Hongmin Li

Jia Zhou

Affiliations

Soon will be listed here.

Abstract

Since time immemorial human beings have constantly been fighting against viral infections. The ongoing and devastating coronavirus disease 2019 pandemic represents one of the most severe and most significant public health emergencies in human history, highlighting an urgent need to develop broad-spectrum antiviral agents. Salicylamide (2-hydroxybenzamide) derivatives, represented by niclosamide and nitazoxanide, inhibit the replication of a broad range of RNA and DNA viruses such as flavivirus, influenza A virus, and coronavirus. Moreover, nitazoxanide was effective in clinical trials against different viral infections including diarrhea caused by rotavirus and norovirus, uncomplicated influenza A and B, hepatitis B, and hepatitis C. In this review, we summarize the broad antiviral activities of salicylamide derivatives, the clinical progress, and the potential targets or mechanisms against different viral infections and highlight their therapeutic potential in combating the circulating and emerging viral infections in the future.

Citing Articles

Antiviral Activity of Nitazoxanide and Miltefosine Against FeHV-1 In Vitro.

Longobardi C, Ferrara G, Damiano S, Florio S, Iovane G, Pagnini U Vet Med Int. 2024; 2024:8849561.

PMID: 39464309 PMC: 11512641. DOI: 10.1155/2024/8849561.

Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022).

Ali S, Zhou J Eur J Med Chem. 2023; 256:115476.

PMID: 37207534 PMC: 10247436. DOI: 10.1016/j.ejmech.2023.115476.

References

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Sleeman K, Mishin V, Guo Z, Garten R, Balish A, Fry A . Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013. Antimicrob Agents Chemother. 2014; 58(4):2045-51. PMC: 4023734. DOI: 10.1128/AAC.02556-13. View

Ilunga Kalenga O, Moeti M, Sparrow A, Nguyen V, Lucey D, Ghebreyesus T . The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018-2019. N Engl J Med. 2019; 381(4):373-383. DOI: 10.1056/NEJMsr1904253. View

Lanata C, Fischer-Walker C, Olascoaga A, Torres C, Aryee M, Black R . Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS One. 2013; 8(9):e72788. PMC: 3762858. DOI: 10.1371/journal.pone.0072788. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Pauk K, Zadrazilova I, Imramovsky A, Vinsova J, Pokorna M, Masarikova M . New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species. Bioorg Med Chem. 2013; 21(21):6574-81. DOI: 10.1016/j.bmc.2013.08.029. View

Weaver S, Osorio J, Livengood J, Chen R, Stinchcomb D . Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines. 2012; 11(9):1087-101. PMC: 3562718. DOI: 10.1586/erv.12.84. View

Atmar R, Baehner F, Cramer J, Lloyd E, Sherwood J, Borkowski A . Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination. J Infect Dis. 2019; 220(4):603-614. DOI: 10.1093/infdis/jiz170. View

Xu J, Shi P, Li H, Zhou J . Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. 2020; 6(5):909-915. PMC: 7098069. DOI: 10.1021/acsinfecdis.0c00052. View

10.

Marrugal-Lorenzo J, Serna-Gallego A, Berastegui-Cabrera J, Pachon J, Sanchez-Cespedes J . Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections. Sci Rep. 2019; 9(1):17. PMC: 6327057. DOI: 10.1038/s41598-018-37290-3. View

11.

Li Z, Xu J, Lang Y, Fan X, Kuo L, DBrant L . JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both and . ACS Infect Dis. 2020; 6(10):2616-2628. PMC: 7559020. DOI: 10.1021/acsinfecdis.0c00217. View

12.

Jeon S, Ko M, Lee J, Choi I, Byun S, Park S . Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrob Agents Chemother. 2020; 64(7). PMC: 7318052. DOI: 10.1128/AAC.00819-20. View

13.

Rossignol J, Kabil S, El-Gohary Y, Elfert A, Keeffe E . Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008; 28(5):574-80. DOI: 10.1111/j.1365-2036.2008.03781.x. View

14.

Robinson C, Singh G, Lee J, Dehghan S, Rajaiya J, Liu E . Molecular evolution of human adenoviruses. Sci Rep. 2013; 3:1812. PMC: 3648800. DOI: 10.1038/srep01812. View

15.

Li Z, Brecher M, Deng Y, Zhang J, Sakamuru S, Liu B . Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res. 2017; 27(8):1046-1064. PMC: 5539352. DOI: 10.1038/cr.2017.88. View

16.

Diggle L . Rotavirus diarrhoea and future prospects for prevention. Br J Nurs. 2007; 16(16):970-4. DOI: 10.12968/bjon.2007.16.16.27074. View

17.

Barrows N, Campos R, Liao K, Prasanth K, Soto-Acosta R, Yeh S . Biochemistry and Molecular Biology of Flaviviruses. Chem Rev. 2018; 118(8):4448-4482. PMC: 5937540. DOI: 10.1021/acs.chemrev.7b00719. View

18.

Xu J, Berastegui-Cabrera J, Chen H, Pachon J, Zhou J, Sanchez-Cespedes J . Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection. J Med Chem. 2020; 63(6):3142-3160. DOI: 10.1021/acs.jmedchem.9b01950. View

19.

Blacklow N, Greenberg H . Viral gastroenteritis. N Engl J Med. 1991; 325(4):252-64. DOI: 10.1056/NEJM199107253250406. View

20.

Mahapatro S, Mahilary N, Satapathy A, Das R . Nitazoxanide in Acute Rotavirus Diarrhea: A Randomized Control Trial from a Developing Country. J Trop Med. 2017; 2017:7942515. PMC: 5346365. DOI: 10.1155/2017/7942515. View